Antibacterial Action of Protein Fraction Isolated from Rapana venosa Hemolymph against Escherichia coli NBIMCC 8785
- PMID: 38256901
- PMCID: PMC10821198
- DOI: 10.3390/ph17010068
Antibacterial Action of Protein Fraction Isolated from Rapana venosa Hemolymph against Escherichia coli NBIMCC 8785
Abstract
Natural products and especially those from marine organisms are being intensively explored as an alternative to synthetic antibiotics. However, the exact mechanisms of their action are not yet well understood. The molecular masses of components in the hemolymph fraction with MW 50-100 kDa from Rapana venosa were determined using ImageQuant™ TL v8.2.0 software based on electrophoretic analysis. Mainly, three types of compounds with antibacterial potential were identified, namely proteins with MW at 50.230 kDa, 62.100 kDa and 93.088 kDa that were homologous to peroxidase-like protein, aplicyanin A and L-amino acid oxidase and functional units with MW 50 kDa from R. venous hemocyanin. Data for their antibacterial effect on Escherichia coli NBIMCC 8785 were obtained by CTC/DAPI-based fluorescent analysis (analysis based on the use of a functional fluorescence probe). The fluorescent analyses demonstrated that a 50% concentration of the fraction with MW 50-100 kDa was able to eliminate 99% of the live bacteria. The antimicrobial effect was detectable even at a 1% concentration of the active compounds. The bacteria in this case had reduced metabolic activity and a 24% decreased size. The fraction had superior action compared with another mollusc product-snail slime-which killed 60% of the E. coli NBIMCC 8785 cells at a 50% concentration and had no effect at a 1% concentration. The obtained results demonstrate the high potential of the fraction with MW 50-100 kDa from R. venosa to eliminate and suppress the development of Escherichia coli NBIMCC 8785 bacteria and could be applied as an appropriate component of therapeutics with the potential to replace antibiotics to avoid the development of antibiotic resistance.
Keywords: Escherichia coli NBIMCC 8785; Rapana venosa hemolymph; antimicrobial effect.
Conflict of interest statement
The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analysis or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Figures







References
-
- World Bank, PRESS RELEASE, 20 September 2016. [(accessed on 18 December 2023)]. Available online: https://www.worldbank.org/en/news/press-release/2016/09/18/by-2050-drug-....
-
- European Commission: A European One Health Action Plan against Antimicrobial Resistance (AMR), Brussels, Belgium, 2017, p. 24. [(accessed on 18 December 2023)]. Available online: http://www.who.int/entity/drugresistance/documents/surveillancereport/en....
-
- World Health Organization Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. 2019. [(accessed on 18 December 2023)]. Available online: http://www.who.int/medicines/publications/global-priority-list-antibioti....
Grants and funding
- National Program "Innovative Low-Toxic and Biologically Active Means for Precision Medicine" - BioActiveMed, grant number Д01-217/30.11.2018/Ministry of Education and Science of the Republic of Bulgaria
- Project BG05M2OP001-1.002-0019: 'Clean Technologies for Sustainable Environment-Waters,Waste, Energy for a Circular Economy'/Operational Program 'Science and education for smart growth', co-financed by the European Union through the European structural and investment funds
LinkOut - more resources
Full Text Sources
Research Materials